As a long term GNBT investor, I believe that it is important to remember that Joe’s GNBT vision was establisher before Covid-19, and is still valid. The Covid vaccine is a side (albeit big) opportunity to put Ii-Key to the test. BARDA funding would be a welcomed unplanned funding source, but the NGIO spin-out was not originally dependent on a Covid vaccine trial..

Caught up in the “warp speed’ mentality, Moderna will conduct their Phase 3 double blind study. No small batch trials, just 30,000 participants. They will be exposed to Covid-19, 15,000 vaccinated, best case scenario, no (presently unknown ) side effects and no virus infections, while the 15,000 placebos being exposed, getting the virus according to their natural immune responses. These volunteers will be real heroes knowing that at the very best, they only have a 50% chance of not getting Covid-19. https://www.nbcnews.com/health/health-news/ma...y-n1234979

As the saying goes; haste makes waste (human?). I think that Ii-Key will prove its value in the long haul. Patience will prove Joe’s vision in the long haul. Besides, does anyone want Generex to be added as a foot note to the following article? https://www.nbcnews.com/business/corporations...g-n1235022